CYBNCYBIN INC.

NYSE cybin.com


$ 0.35 $ 0.00 (0 %)    

Wednesday, 01-May-2024 15:58:22 EDT
QQQ $ 424.46 $ -0.78 (-0.18 %)
DIA $ 379.90 $ 1.00 (0.26 %)
SPY $ 502.50 $ -1.90 (-0.38 %)
TLT $ 88.14 $ -0.08 (-0.09 %)
GLD $ 211.90 $ -1.89 (-0.88 %)
$ 0.35
$ 0.34
$ 0.34 x 300
$ 0.00 x 0
$ 0.34 - $ 0.35
$ 0.21 - $ 0.74
2,390,025
na
68.37M
$ 0.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

 cybin-announces-end-of-phase-2-meeting-with-fda-for-cyb003-in-major-depressive-disorder-and-phase-3-program-design

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company co...

 hc-wainwright--co-maintains-buy-on-cybin-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio maintains Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

 cybin-inc-q3-earnings-clinical-advances-amid-financial-loss

The TDR Three Key Takeaways:

 hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

Core News & Articles

https://www.marijuanamoment.net/fda-grants-priority-review-of-mdma-assisted-therapy-for-ptsd-psychedelics-drug-development-comp...

 cybin-reveals-grant-of-two-additional-patents-in-japan-in-support-of-its-dmt-program

The patents, which are expected to provide exclusivity until at least 2040 and 2041, respectively, include protection for a syn...

 psyched-suggestibility-and-psychedelics-effects-eus-7m-research-fund-australias-treatment-delivery-bz-podcast-and-more

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedel...

 fda-green-lights-cybins-psychedelic-clinical-study-assessing-generalized-anxiety

Cybin will advance the clinical development of the novel psychedelic molecule CYB004 for generalized anxiety treatment.

 psychedelics-headlines-mdma--coping-skills-in-ptsd-lsds-perceived-risks-knowledge-gaps-surveys--more

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week ...

 psyched-100m-for-mdma-therapy-va-funds-2024-watchlist-reform-updates-and-more

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION